AMRI Names Key Leader to Oversee Pharmaceutical Development and Manufacturing.

ALBANY, N.Y. -- Albany Molecular Research, Inc. (NASDAQ: AMRI) has named Jonathan D. Evans as vice president of pharmaceutical development and manufacturing.

In this newly created position, Mr. Evans will assume responsibility for AMRI's Chemical Development, Small Scale cGMP Manufacturing, Analytical, Quality Control Quality Assurance, and Large Scale Commercial Manufacturing business components, including operations in both Albany and Syracuse, New York; Hyderabad, India; as well as AMRI's Large Scale Manufacturing facility in Rensselaer, New York. In addition, he will serve as a key advisor to AMRI Chairman, President and CEO Thomas E. D'Ambra, Ph.D., and as a member of the company's senior leadership team.

Mr. Evans brings 16 years of experience in operations and management, including 13 years at General Electric's Advanced Materials Division. He began his career at GE in 1994 as a mechanical engineering leader in Waterford, New York. In 1997, he was promoted to plant manager - fluids and specialties. He was then promoted to operations manager - coatings and resins, where he focused on improving efficiency, global logistics and customer service. In 2000, Mr. Evans led the integration of a newly acquired consumer products business. After managing supply chain operations in Leverkusen, Germany, he returned to Waterford as global business manager for the elastomers/specialty sealants business, where he identified business development opportunities and oversaw the manufacturing plan for a startup plant in Thailand. Soon after, he became general manager - specialty operations, leading plants in North and South America. Under his leadership, the business increased profitability and oversaw significant improvements in the occupational safety and environmental areas. Most recently, Mr. Evans was general manager of elastomers/specialty polymers, where he led an international team responsible for global business development and global marketing.

Mr. Evans holds a bachelor's degree in mechanical engineering from Clarkson University and a master's degree in business management from Rensselaer Polytechnic Institute. In addition, he served as a platoon leader in the U.S. Army from 1991 to 1994.

"We are pleased to announce the addition of Jonathan Evans to AMRI's senior leadership team," said D'Ambra. "Jon has compiled an exceptional track record at General Electric, and we expect him to play a key leadership role in the ongoing restructuring of our Large Scale Manufacturing operations. His background includes technical, engineering expertise coupled with business acumen and experience in a wide range of business functions, from manufacturing operations to business development. His prior roles integrating corporate acquisitions and reengineering supply chain operations at GE will be key skill sets as we continue to improve operational efficiency, customer service and bottom-line performance. I look forward to working with him."

Founded in 1991, AMRI provides scientific services, technologies and products that improve quality of life while delivering excellence, value and maximum return. AMRI's core business consists of a fee-for service contract services platform encompassing drug discovery, development and manufacturing; and a separate, standalone R&D division comprising proprietary technologies, internal drug discovery and bundled capabilities designed for more collaborative relationships. With locations in the U.S., Europe, and Asia, AMRI provides customers with a range of services and cost models.

Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. These statements may be identified by forward-looking words such as "may," "could," "should," "would," "will," "intend," "expect," "anticipate," "believe" and "continue" or similar words. Readers should not place undue reliance on our forward-looking statements. The company's actual results may differ materially from such forward-looking statements as a result of numerous factors, some of which the company may not be able to predict and may not be within the company's control. Factors that could cause such differences include, but are not limited to the company's ability to attract and retain experienced scientists, trends in pharmaceutical and biotechnology companies outsourcing of chemical research and development, the company's ability to enforce its intellectual property and technology rights, the risks posed by international operations to the company, and the company's ability to effectively manage its growth as well as those factors discussed in the company's Annual Report on Form 10-K for the year ended December 31, 2005 as filed with the Securities and Exchange Commission on March 16, 2006 and the company's other SEC filings. The company does not undertake any duty to and does not intend to update any forward-looking statements contained in this press release after the date of this press release.